Opportunity Information: Apply for PAR 16 017
Apply for PAR 16 017
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Novel Genomic Technology Development Direct to Phase II SBIR (R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172,.
- This funding opportunity was created on Oct 27, 2015 and posted on Oct 27, 2015.
- Applicants must submit their applications by Jan 11, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Novel Genomic Technology Development Direct to Phase II SBIR (R44) opportunity (Funding Opportunity Number PAR 16 017) is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant program run under the U.S. Department of Health and Human Services. It is designed specifically for eligible small businesses that are ready to move directly into a Phase II SBIR project, meaning the applicant is expected to have already completed early proof-of-concept work and to be prepared to carry out a more advanced, development-focused effort without first seeking Phase I SBIR support under this announcement.
The central purpose of the announcement is to catalyze major advances in genomics by funding the development of novel, high-impact genomic technologies. A key detail is that this program is aimed at technology development beyond nucleic acid sequencing itself. In other words, while sequencing is a core part of genomics, this FOA is looking for innovations across the broader ecosystem of genomics tools and methods rather than incremental or primary advances in sequencing platforms. The emphasis is on enabling technologies that can substantially improve what researchers and clinicians can measure, interpret, or do with genomic information.
This FOA is explicitly geared toward projects that are very novel and have the potential for outsized impact. The announcement frames its intent as supporting high-risk, high-reward development work that could shift the field in meaningful ways, rather than routine product refinements. The expectation is that the funded technology could materially affect genomics research or applications within the next three to five years, so the program is looking for ideas that are ambitious but also plausibly executable on a near-term horizon. That time frame implies a preference for approaches that are far enough along to be developed, validated, and positioned for adoption relatively quickly, rather than long-range basic research efforts with uncertain pathways to use.
Administratively, the opportunity is categorized as a discretionary grant with a health-related funding activity category, tied to CFDA numbers 93.172 (and listed also as 93.), and administered by NIH (listed as HHS-NIH11). The eligible applicant pool is limited to small businesses, consistent with SBIR rules and the R44 mechanism. The FOA was posted on October 27, 2015, with a closing date of January 11, 2017 (original and current closing dates are the same in the provided record). The source data provided does not specify an award ceiling or the expected number of awards, so applicants would typically need to refer to the full FOA text for budget limits, project period expectations, and any institute-specific funding considerations.
In practical terms, this funding opportunity is best understood as NIH creating a fast lane for small companies with compelling preliminary data to push transformative genomics technologies through a substantial development phase. The overarching message is clear: bring forward a genomics technology concept that is not simply a sequencing improvement, demonstrate readiness for Phase II-level work, and propose a development plan with a realistic path to delivering a tool that could meaningfully change genomics capabilities within a three-to-five-year window.
FAQs: Novel Genomic Technology Development Direct to Phase II SBIR (R44) - PAR 16-017
What is this funding opportunity?
This is the Novel Genomic Technology Development Direct to Phase II SBIR (R44) opportunity, Funding Opportunity Number PAR 16-017. It is an NIH Small Business Innovation Research (SBIR) grant program under the U.S. Department of Health and Human Services (HHS).
Who runs and administers this program?
The program is administered by the National Institutes of Health (NIH), listed as HHS-NIH11 in the provided record.
What type of funding mechanism is used?
The opportunity uses the SBIR R44 mechanism and is specifically a Direct to Phase II SBIR pathway.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with SBIR rules and the R44 mechanism.
What does "Direct to Phase II" mean in this announcement?
Direct to Phase II means the applicant is expected to have already completed early proof-of-concept work and to be ready to begin a Phase II-level, development-focused project without first applying for Phase I SBIR support under this announcement.
Is Phase I SBIR support available under this announcement?
No. This opportunity is structured so that applicants move directly into a Phase II SBIR project and are expected to be beyond early proof-of-concept.
What is the main purpose of the FOA?
The central purpose is to catalyze major advances in genomics by funding the development of novel, high-impact genomic technologies.
What kinds of projects is NIH looking to fund?
The FOA targets very novel, high-impact genomic technology development projects, emphasizing high-risk, high-reward development work that could shift the field in meaningful ways rather than routine or incremental product refinements.
Is this FOA focused on improving DNA/RNA sequencing platforms?
No. A key detail is that this program is aimed at technology development beyond nucleic acid sequencing itself. While sequencing is foundational to genomics, this FOA emphasizes innovations across the broader ecosystem of genomics tools and methods rather than primary or incremental advances in sequencing platforms.
What does "beyond sequencing" mean in the context of this opportunity?
Based on the provided description, "beyond sequencing" refers to enabling technologies and methods in the broader genomics ecosystem that substantially improve what researchers or clinicians can measure, interpret, or do with genomic information, without being framed as sequencing platform improvements.
How novel does a project need to be?
This FOA is explicitly geared toward projects that are very novel and have the potential for outsized impact, with an emphasis on transformative, not routine, development.
What level of risk and reward is expected?
The announcement frames the intent as supporting high-risk, high-reward development work that could meaningfully shift the field of genomics.
What is the expected impact timeline for funded technologies?
The expectation is that the funded technology could materially affect genomics research or applications within the next three to five years.
Does the FOA favor near-term development over long-range basic research?
Yes. The three-to-five-year impact expectation implies a preference for approaches that are far enough along to be developed, validated, and positioned for adoption relatively quickly, rather than long-range basic research efforts with uncertain pathways to use.
What should an applicant be able to demonstrate to be a good fit?
Based on the description provided, a strong fit would include (1) compelling preliminary work supporting readiness for Phase II-level development, (2) a proposal focused on a novel genomic technology beyond sequencing, and (3) a development plan that can realistically deliver a tool with meaningful impact within roughly three to five years.
What is the funding activity category?
The opportunity is categorized as a discretionary grant with a health-related funding activity category.
What CFDA number is associated with this opportunity?
The record ties the opportunity to CFDA 93.172 (and also lists it as 93.).
When was the opportunity posted?
The FOA was posted on October 27, 2015.
What is the application closing date?
The closing date provided is January 11, 2017 (the original and current closing dates are the same in the provided record).
Are the award amount limits or number of awards specified in the provided information?
No. The source data provided does not specify an award ceiling or the expected number of awards.
Where would an applicant typically find budget limits and project period expectations?
Because the provided record does not include an award ceiling, expected number of awards, budget limits, or project period expectations, applicants would typically need to refer to the full FOA text for those details and for any institute-specific funding considerations.
What is the practical "takeaway" for potential applicants?
This opportunity functions as a fast lane for small companies with compelling preliminary data to pursue substantial Phase II development of transformative genomics technologies that are not simply sequencing improvements, with a realistic path to impact within three to five years.
Browse more opportunities from the same agency: HHS-NIH11
Browse more opportunities from the same category: Health
Next opportunity: High-End Instrumentation (HEI) Grant Program (S10)
Previous opportunity: Manufacturing Innovation Institutes
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 017
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 017) also looked into and applied for these:
| Funding Opportunity |
|---|
| High-End Instrumentation (HEI) Grant Program (S10) Apply for PAR 16 053 Funding Number: PAR 16 053 Agency: HHS-NIH11 Category: Health Funding Amount: $2,000,000 |
| Research on the Epidemiology, Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in Southeast Asia and the Western Pacific Apply for RFA IP 16 001 Funding Number: RFA IP 16 001 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: $3,000,000 |
| Supporting the National Blood Transfusion Service (NBTS) in the implementation and strengthening of Blood Safety activities in the Republic of Uganda under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10260501SUPP16 Funding Number: CDC RFA PS10 10260501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $927,809 |
| National Child Traumatic Stress Initiative – Category III Community Treatment and Services (CTS) Centers Apply for SM 16 005 Funding Number: SM 16 005 Agency: HHS-SAMHS Category: Health Funding Amount: $400,000 |
| Implementation of Programs to Support Integration of Health Information Systems and HIV/AIDS/TB Treatment Services in the Republic of Zambia under the President’s Emergency Plan for AIDS (PEPFAR) Apply for CDC RFA GH16 1669 Funding Number: CDC RFA GH16 1669 Agency: HHS-CDC-CGH Category: Health Funding Amount: $10,000,000 |
| Enhanced surveillance in the Republic of Uganda under the President’s Emergency Plan for AIDS relief (PEPFAR) Apply for CDC RFA GH11 116505CONT16 Funding Number: CDC RFA GH11 116505CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Supporting the Scale up of Comprehensive HIV/AIDS Prevention Services in the Republic of Uganda under PEPFAR Apply for CDC RFA PS10 10200501SUPP16 Funding Number: CDC RFA PS10 10200501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $1,562,149 |
| Leadership Education in Neurodevelopmental and Other Related Disabilities (LEND) Apply for HRSA 16 031 Funding Number: HRSA 16 031 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Precision Medicine Initiative Cohort Program Biobank (U24) Apply for RFA PM 16 004 Funding Number: RFA PM 16 004 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Strengthening Community-Based HIV/AIDS Prevention and Care Services in the Underserved Northern and Western Regions of the Republic of Côte d’Ivoire Under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10330501SUPP16 Funding Number: CDC RFA PS10 10330501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $3,470,000 |
| Novel Genomic Technology Development (R01) Apply for PAR 16 014 Funding Number: PAR 16 014 Agency: HHS-NIH11 Category: Health Funding Amount: $700,000 |
| Nurse Education, Practice, Quality and Retention – Bachelor of Science in Nursing Practicums in Community Settings Program Apply for HRSA 16 066 Funding Number: HRSA 16 066 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Reinforcing HIV Clinical Services within a Network of Public Health Institutions in the Central Plateau and the Lower Artibonite of Haiti under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1712 Funding Number: CDC RFA GH16 1712 Agency: HHS-CDC-CGH Category: Health Funding Amount: $7,500,000 |
| International Centers of Excellence for Malaria Research (U19) Apply for RFA AI 15 056 Funding Number: RFA AI 15 056 Agency: HHS-NIH11 Category: Health Funding Amount: $1,000,000 |
| Strengthening Epidemiology and Strategic Information in the Republic of Zimbabwe under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1675 Funding Number: CDC RFA GH16 1675 Agency: HHS-CDC-CGH Category: Health Funding Amount: $2,010,000 |
| NHLBI Progenitor Cell Translational Consortium Coordinating Center (U24) Apply for RFA HL 16 022 Funding Number: RFA HL 16 022 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition - Stimulating Peripheral Activity to Relieve Conditions (SPARC): Foundational Functional Mapping of Neuroanatomy and Neurobiology of Organs (OT2) Apply for RFA RM 15 020 Funding Number: RFA RM 15 020 Agency: HHS-NIH11 Category: Health Funding Amount: $600,000 |
| Service Area Competition Apply for HRSA 16 008 Funding Number: HRSA 16 008 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Protecting the Advances in Polio, Rubella and Measles Elimination: Strengthening Immunization Programs in the Americas. Apply for CDC RFA GH14 140103CONT16 Funding Number: CDC RFA GH14 140103CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| USAID Regional Health Integration to Enhance Services in East Central Uganda (USAID RHITES EC) Apply for RFA 617 16 000001 Funding Number: RFA 617 16 000001 Agency: USAID-UGA Category: Health Funding Amount: $57,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 017", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.